NanoViricides

NNVC · NYSE American

$1.48+$0.18 (+13.85%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.30

NNVC analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $6.12 (+313.5% upside)

Low: $6.06
Now: $1.48
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

NNVC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Noble Capital Markets	Jul 6, 2026	Initiates	Outperform	$6.00	28%

The case for and against

Updated Nov 6, 2024

Bull case

Nanoviricides Inc demonstrates a promising financial trajectory due to the extension of its line of credit until late December 2025, which enhances its cash flow and liquidity position during critical clinical development phases. The company's management is optimistic about the transformative potential of its antiviral platform, particularly with NV-387 showing considerable effectiveness against various influenza strains, thus positioning it favorably in the competitive landscape of antiviral treatments. Furthermore, the exploration of innovative therapies targeting herpes, RSV, and smallpox suggests a diversified pipeline that could lead to future revenue generation, reinforcing a positive outlook on the company's financial health and growth potential.

Bear case

Nanoviricides Inc. has reported a negative cash outflow of $1.7 million for the December quarter, indicating increased operational expenditures that are projected to rise further as the company engages in clinical trials between July 2024 and June 2025. This anticipated higher cash burn underscores concerns regarding the need for future capital raising, which may lead to equity dilution for existing shareholders. Additionally, the inherent development risks associated with Nanoviricides' technology, compounded by the typical higher risk profile of biotech stocks, further contribute to a cautious outlook on the company's stock performance and the viability of its drug candidates.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.